FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1
PMA: P160002
·
Supplement: S015
·
Decision Sep 28, 2021
Classifications
1
FEI Numbers
4
Registration Numbers
4
Basic Information
- Device Name
- Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1
- Trade Name
- VENTANA PD-L1 (SP142) Assay
- PMA Number
- P160002
- Supplement Number
- S015
- Device Class
- FDA Class 3
- Product Code
- PLS
- Generic Name
- Immunohistochemistry assay, antibody, programmed death-ligand 1
- Medical Specialty
- Unknown
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- September 28, 2021
- Date Received
- September 7, 2021
- Supplement Type
- Special (Immediate Track)
- Supplement Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited Review
- N
Advisory Committee Statement
Approved for removal of the triple negative breast cancer (TNBC) indication from the device intended use statement and labeling.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PLS | Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 | FDA class 3 | Unknown |